Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19

V. Tomášková, A. Mýtniková, M. Hortová Kohoutková, O. Mrkva, M. Skotáková, M. Šitina, K. Helánová, J. Frič, J. Pařenica, V. Šrámek, M. Helán

. 2022 ; 9 (-) : 972040. [pub] 20220831

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023402

Sepsis is a clinical syndrome characterized by a dysregulated response to infection. It represents a leading cause of mortality in ICU patients worldwide. Although sepsis is in the point of interest of research for several decades, its clinical management and patient survival are improving slowly. Monitoring of the biomarkers and their combinations could help in early diagnosis, estimation of prognosis and patient's stratification and response to the treatment. Circulating soluble endoglin (sEng) is the cleaved extracellular part of transmembrane glycoprotein endoglin. As a biomarker, sEng has been tested in several pathologic conditions where its elevation was associated with endothelial dysfunction. In this study we have tested the ability of sEng to predict mortality and its correlation with other clinical characteristics in the cohort of septic shock patients (n = 37) and patients with severe COVID-19 (n = 40). In patients with COVID-19 sEng did not predict mortality or correlate with markers of organ dysfunction. In contrast, in septic shock the level of sEng was significantly higher in patients with early mortality (p = 0.019; AUC = 0.801). Moreover, sEng levels correlated with signs of circulatory failure (required dose of noradrenalin and lactate levels; p = 0.002 and 0.016, respectively). The predominant clinical problem in patients with COVID-19 was ARDS, and although they often showed signs of other organ dysfunction, circulatory failure was exceptional. This potentially explains the difference between sEng levels in COVID-19 and septic shock. In conclusion, we have confirmed that sEng may reflect the extent of the circulatory failure in septic shock patients and thus could be potentially used for the early identification of patients with the highest degree of endothelial dysfunction who would benefit from endothelium-targeted individualized therapy.

000      
00000naa a2200000 a 4500
001      
bmc22023402
003      
CZ-PrNML
005      
20221031095219.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2022.972040 $2 doi
035    __
$a (PubMed)36117974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tomášková, Veronika $u Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19 / $c V. Tomášková, A. Mýtniková, M. Hortová Kohoutková, O. Mrkva, M. Skotáková, M. Šitina, K. Helánová, J. Frič, J. Pařenica, V. Šrámek, M. Helán
520    9_
$a Sepsis is a clinical syndrome characterized by a dysregulated response to infection. It represents a leading cause of mortality in ICU patients worldwide. Although sepsis is in the point of interest of research for several decades, its clinical management and patient survival are improving slowly. Monitoring of the biomarkers and their combinations could help in early diagnosis, estimation of prognosis and patient's stratification and response to the treatment. Circulating soluble endoglin (sEng) is the cleaved extracellular part of transmembrane glycoprotein endoglin. As a biomarker, sEng has been tested in several pathologic conditions where its elevation was associated with endothelial dysfunction. In this study we have tested the ability of sEng to predict mortality and its correlation with other clinical characteristics in the cohort of septic shock patients (n = 37) and patients with severe COVID-19 (n = 40). In patients with COVID-19 sEng did not predict mortality or correlate with markers of organ dysfunction. In contrast, in septic shock the level of sEng was significantly higher in patients with early mortality (p = 0.019; AUC = 0.801). Moreover, sEng levels correlated with signs of circulatory failure (required dose of noradrenalin and lactate levels; p = 0.002 and 0.016, respectively). The predominant clinical problem in patients with COVID-19 was ARDS, and although they often showed signs of other organ dysfunction, circulatory failure was exceptional. This potentially explains the difference between sEng levels in COVID-19 and septic shock. In conclusion, we have confirmed that sEng may reflect the extent of the circulatory failure in septic shock patients and thus could be potentially used for the early identification of patients with the highest degree of endothelial dysfunction who would benefit from endothelium-targeted individualized therapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mýtniková, Alexandra $u Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Hortová Kohoutková, Marcela $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Mrkva, Ondřej $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Skotáková, Monika $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Šitina, Michal $u Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Helánová, Kateřina $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Cardiology, University Hospital Brno, Brno, Czechia
700    1_
$a Frič, Jan $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Modern Immunotherapy Research, Institute of Hematology and Blood Transfusion, Prague, Czechia
700    1_
$a Pařenica, Jiří $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Cardiology, University Hospital Brno, Brno, Czechia
700    1_
$a Šrámek, Vladimír $u Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Helán, Martin $u Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 9, č. - (2022), s. 972040
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36117974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095217 $b ABA008
999    __
$a ind $b bmc $g 1853851 $s 1174690
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 9 $c - $d 972040 $e 20220831 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...